Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Trial Profile

A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms PLEIADES
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 15 Sep 2019 Results presented in a Janssen Pharmaceutical Media Release
    • 15 Sep 2019 According to a Janssen Pharmaceutical media release, data were presented at the IMW meeting.
    • 19 Aug 2019 According to a Genmab Media Release, data from this trial will be presented during oral sessions at the 17th International Myeloma Workshop, taking place in Boston, Massachusetts from September 12 to 15, 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top